NCT05710666 2024-08-05Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)Cancer Trials IrelandPhase 2 Active not recruiting11 enrolled